High-dose somatostatin analogues’ effects on glycolipid metabolism in patients with neuroendocrine tumors

#3799

Introduction: Somatostatin analogues (SSAs), octreotide and lanreotide, represent the cornerstone medical therapy of both sporadic and hereditary G1-G2 neuroendocrine tumors (NETs). Changes in glucose metabolism have been shown to occur during standard-dose SSA therapy, but no changes during high-dose therapy have been evaluated.

Aim(s): Analyse changes in glycolipid metabolism in NET patients during high-dose SSAs therapy.

Materials and methods: Clinical data of patients with G1/G2 NET treated with high doses of SSA (Octreotide 30 mg, 1 fl intramuscular every 21 days; Octreotide 60 mg, 1 fl intramuscular every 28 days or Lanreotide 120 mg, 1 fl subcutaneous every 21 or every 14 days), followed at the NET Unit of Federico II University of Naples (ENETS CoE) from 1998 to 2022, were retrospectively evaluated. An evaluation of biochemical and glycometabolic parameters was performed before starting treatment and after 6 months. Diabetic patients were excluded from the analysis.

Conference:

Presenting Author:

Authors: Liccardi A, Minotta R, Cannavale G, Benevento E, Modica R,

Keywords: neuroendocrine tumor, somatostatin analogues, lipid, hyperglycaemia, high dose SSA, glycolipid metabolism,